Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vistakon Pharmaceuticals
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• history of positive diagnostic test for ragweed within the past 2 years;

• positive bilateral response to ragweed as induced by conjunctival allergen challenge

Exclusion Criteria:

• ocular infection;

• history of retinal detachment, diabetic neuropathy, or any progressive retinal disease;

• moderate to severe asthma;

• dry eye syndrome;

• history of severe, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal or autoimmune disease;

• pregnancy or lactation